The global age-related macular degeneration market size was valued at USD 11.6 billion in 2025 and is projected to grow from USD 12.5 billion in 2026 to USD 22.7 billion by 2033, at a CAGR of 9.0% from 2026 to 2033. The market in North America dominated with a revenue share of 53.9% in 2025. The market is driven by the increasing burden of the aging population, as AMD remains one of the leading causes of irreversible vision loss among older adults.
The market is supported by growing disease awareness, improvements in retinal imaging technologies such as optical coherence tomography (OCT), and broader access to specialist ophthalmology services, enabling earlier diagnosis and timely treatment. Anti-vascular endothelial growth factor (anti-VEGF) therapies remain the standard of care for neovascular (wet) AMD, while the introduction of complement pathway inhibitors has expanded treatment options for geographic atrophy in dry AMD. Ongoing research in sustained-release drug delivery systems, gene therapies, and novel biologics is strengthening the development pipeline and addressing the need to reduce treatment burden. At the same time, increasing healthcare expenditure, expanding retinal care infrastructure in developing countries, and the growing involvement of pharmaceutical and biotechnology companies in ophthalmology are supporting steady market growth across both developed and emerging regions.
This product will be delivered within 1-3 business days.
The market is supported by growing disease awareness, improvements in retinal imaging technologies such as optical coherence tomography (OCT), and broader access to specialist ophthalmology services, enabling earlier diagnosis and timely treatment. Anti-vascular endothelial growth factor (anti-VEGF) therapies remain the standard of care for neovascular (wet) AMD, while the introduction of complement pathway inhibitors has expanded treatment options for geographic atrophy in dry AMD. Ongoing research in sustained-release drug delivery systems, gene therapies, and novel biologics is strengthening the development pipeline and addressing the need to reduce treatment burden. At the same time, increasing healthcare expenditure, expanding retinal care infrastructure in developing countries, and the growing involvement of pharmaceutical and biotechnology companies in ophthalmology are supporting steady market growth across both developed and emerging regions.
Global Age-related Macular Degeneration Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global Age-related macular degeneration market report based on product, disease, distribution channel, and region:Product Outlook (Revenue, USD Million, 2021 - 2033)
- Eylea
- Lucentis
- Beovu
- Others
Disease Outlook (Revenue, USD Million, 2021 - 2033)
- Wet AMD
- Dry AMD
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. The internal database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. The internal database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Age-related Macular Degeneration Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Age-related Macular Degeneration Market: Product Business Analysis
4.1. Product Market Share, 2025 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, Product, 2021 to 2033 (USD Billion)
4.4. Eylea
4.4.1. Eylea Market, 2021 - 2033 (USD Billion)
4.5. Lucentis
4.5.1. Lucentis Market, 2021 - 2033 (USD Billion)
4.6. Beovu
4.6.1. Beovu Market, 2021 - 2033 (USD Billion)
4.7. Others
4.7.1. Others Market, 2021 - 2033 (USD Billion)
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, Product, 2021 to 2033 (USD Billion)
4.4. Eylea
4.4.1. Eylea Market, 2021 - 2033 (USD Billion)
4.5. Lucentis
4.5.1. Lucentis Market, 2021 - 2033 (USD Billion)
4.6. Beovu
4.6.1. Beovu Market, 2021 - 2033 (USD Billion)
4.7. Others
4.7.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 5. Age-related Macular Degeneration Market: Disease Business Analysis
5.1. Disease Market Share, 2025 & 2033
5.2. Disease Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, Disease, 2021 to 2033 (USD Billion)
5.4. Wet AMD
5.4.1. Wet AMD Market, 2021 - 2033 (USD Billion)
5.5. Dry AMD
5.5.1. Dry AMD Market, 2021 - 2033 (USD Billion)
5.2. Disease Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, Disease, 2021 to 2033 (USD Billion)
5.4. Wet AMD
5.4.1. Wet AMD Market, 2021 - 2033 (USD Billion)
5.5. Dry AMD
5.5.1. Dry AMD Market, 2021 - 2033 (USD Billion)
Chapter 6. Age-related Macular Degeneration Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2025 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, Distribution Channel, 2021 to 2033 (USD Billion)
6.4. Hospital Pharmacy
6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
6.5. Retail Pharmacy
6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Billion)
6.6. Online Pharmacy
6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Billion)
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, Distribution Channel, 2021 to 2033 (USD Billion)
6.4. Hospital Pharmacy
6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
6.5. Retail Pharmacy
6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Billion)
6.6. Online Pharmacy
6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Billion)
Chapter 7. Age-related Macular Degeneration Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2025 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America Age-related Macular Degeneration Market Estimates and Forecasts, Country, 2021 - 2033 (USD Billion)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Framework
7.4.2.5. U.S. Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Framework
7.4.3.5. Canada Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Framework
7.4.4.5. Mexico Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5. Europe
7.5.1. Europe Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Framework
7.5.2.5. UK Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Framework
7.5.3.5. Germany Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Framework
7.5.4.5. France Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Framework
7.5.5.5. Italy Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Target Disease Prevalence
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Framework
7.5.6.5. Spain Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Target Disease Prevalence
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Framework
7.5.7.5. Denmark Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Target Disease Prevalence
7.5.8.3. Regulatory Framework
7.5.8.4. Reimbursement Framework
7.5.8.5. Sweden Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Target Disease Prevalence
7.5.9.3. Regulatory Framework
7.5.9.4. Reimbursement Framework
7.5.9.5. Norway Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6. Asia Pacific
7.6.1. Asia Pacific Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Framework
7.6.2.5. Japan Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Framework
7.6.3.5. China Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Framework
7.6.4.5. India Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Framework
7.6.5.5. Australia Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Regulatory Framework
7.6.6.4. Reimbursement Framework
7.6.6.5. South Korea Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Target Disease Prevalence
7.6.7.3. Regulatory Framework
7.6.7.4. Reimbursement Framework
7.6.7.5. Thailand Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7. Latin America
7.7.1. Latin America Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Target Disease Prevalence
7.7.2.3. Regulatory Framework
7.7.2.4. Reimbursement Framework
7.7.2.5. Brazil Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Target Disease Prevalence
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Framework
7.7.3.5. Argentina Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Target Disease Prevalence
7.8.2.3. Regulatory Framework
7.8.2.4. Reimbursement Framework
7.8.2.5. South Africa Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Target Disease Prevalence
7.8.3.3. Regulatory Framework
7.8.3.4. Reimbursement Framework
7.8.3.5. Saudi Arabia Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Target Disease Prevalence
7.8.4.3. Regulatory Framework
7.8.4.4. Reimbursement Framework
7.8.4.5. UAE Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Target Disease Prevalence
7.8.5.3. Regulatory Framework
7.8.5.4. Reimbursement Framework
7.8.5.5. Kuwait Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America Age-related Macular Degeneration Market Estimates and Forecasts, Country, 2021 - 2033 (USD Billion)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Framework
7.4.2.5. U.S. Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Framework
7.4.3.5. Canada Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Framework
7.4.4.5. Mexico Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5. Europe
7.5.1. Europe Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Framework
7.5.2.5. UK Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Framework
7.5.3.5. Germany Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Framework
7.5.4.5. France Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Framework
7.5.5.5. Italy Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Target Disease Prevalence
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Framework
7.5.6.5. Spain Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Target Disease Prevalence
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Framework
7.5.7.5. Denmark Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Target Disease Prevalence
7.5.8.3. Regulatory Framework
7.5.8.4. Reimbursement Framework
7.5.8.5. Sweden Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Target Disease Prevalence
7.5.9.3. Regulatory Framework
7.5.9.4. Reimbursement Framework
7.5.9.5. Norway Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6. Asia Pacific
7.6.1. Asia Pacific Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Framework
7.6.2.5. Japan Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Framework
7.6.3.5. China Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Framework
7.6.4.5. India Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Framework
7.6.5.5. Australia Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Regulatory Framework
7.6.6.4. Reimbursement Framework
7.6.6.5. South Korea Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Target Disease Prevalence
7.6.7.3. Regulatory Framework
7.6.7.4. Reimbursement Framework
7.6.7.5. Thailand Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7. Latin America
7.7.1. Latin America Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Target Disease Prevalence
7.7.2.3. Regulatory Framework
7.7.2.4. Reimbursement Framework
7.7.2.5. Brazil Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Target Disease Prevalence
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Framework
7.7.3.5. Argentina Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Target Disease Prevalence
7.8.2.3. Regulatory Framework
7.8.2.4. Reimbursement Framework
7.8.2.5. South Africa Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Target Disease Prevalence
7.8.3.3. Regulatory Framework
7.8.3.4. Reimbursement Framework
7.8.3.5. Saudi Arabia Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Target Disease Prevalence
7.8.4.3. Regulatory Framework
7.8.4.4. Reimbursement Framework
7.8.4.5. UAE Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Target Disease Prevalence
7.8.5.3. Regulatory Framework
7.8.5.4. Reimbursement Framework
7.8.5.5. Kuwait Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Novartis AG
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Bayer AG
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Pfizer Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. F. Hoffmann-La Roche Ltd.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Bausch Health Companies Inc.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Regeneron Pharmaceuticals Inc.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Amgen Inc.
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Biogen
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Samsung Bioepis
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Novartis AG
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Bayer AG
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Pfizer Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. F. Hoffmann-La Roche Ltd.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Bausch Health Companies Inc.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Regeneron Pharmaceuticals Inc.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Amgen Inc.
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Biogen
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Samsung Bioepis
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global Age-related macular degeneration market, region, 2021 - 2033 (USD Billion)
Table 4. Global Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 5. Global Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 6. Global Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 7. North America Age-related macular degeneration market, country, 2021 - 2033 (USD Billion)
Table 8. North America Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 9. North America Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 10. North America Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 11. U.S. Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 12. U.S. Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 13. U.S. Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 14. Canada Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 15. Canada Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 16. Canada Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 17. Mexico Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 18. Mexico Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 19. Mexico Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 20. Europe Age-related macular degeneration market, country, 2021 - 2033 (USD Billion)
Table 21. Europe Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 22. Europe Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 23. Europe Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 24. UK Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 25. UK Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 26. UK Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 27. Germany Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 28. Germany Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 29. Germany Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 30. France Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 31. France Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 32. France Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 33. Italy Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 34. Italy Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 35. Italy Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 36. Spain Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 37. Spain Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 38. Spain Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 39. Norway Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 40. Norway Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 41. Norway Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 42. Denmark Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 43. Denmark Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 44. Denmark Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 45. Sweden Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 46. Sweden Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 47. Sweden Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 48. Asia Pacific Age-related macular degeneration market, country, 2021 - 2033 (USD Billion)
Table 49. Asia Pacific Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 50. Asia Pacific Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 51. Asia Pacific Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 52. Japan Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 53. Japan Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 54. Japan Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 55. China Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 56. China Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 57. China Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 58. India Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 59. India Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 60. India Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 61. Australia Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 62. Australia Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 63. Australia Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 64. South Korea Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 65. South Korea Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 66. South Korea Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 67. Thailand Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 68. Thailand Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 69. Thailand Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 70. Latin America Age-related macular degeneration market, country, 2021 - 2033 (USD Billion)
Table 71. Latin America Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 72. Latin America Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 73. Latin America Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 74. Brazil Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 75. Brazil Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 76. Brazil Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 77. Argentina Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 78. Argentina Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 79. Argentina Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 80. Middle East & Africa Age-related macular degeneration market, country, 2021 - 2033 (USD Billion)
Table 81. Middle East & Africa Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 82. Middle East & Africa Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 83. Middle East & Africa Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 84. South Africa Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 85. South Africa Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 86. South Africa Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 87. Saudi Arabia Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 88. Saudi Arabia Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 89. Saudi Arabia Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 90. UAE Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 91. UAE Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 92. UAE Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 93. Kuwait Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 94. Kuwait Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 95. Kuwait Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 2. List of abbreviations
Table 3. Global Age-related macular degeneration market, region, 2021 - 2033 (USD Billion)
Table 4. Global Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 5. Global Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 6. Global Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 7. North America Age-related macular degeneration market, country, 2021 - 2033 (USD Billion)
Table 8. North America Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 9. North America Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 10. North America Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 11. U.S. Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 12. U.S. Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 13. U.S. Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 14. Canada Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 15. Canada Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 16. Canada Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 17. Mexico Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 18. Mexico Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 19. Mexico Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 20. Europe Age-related macular degeneration market, country, 2021 - 2033 (USD Billion)
Table 21. Europe Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 22. Europe Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 23. Europe Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 24. UK Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 25. UK Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 26. UK Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 27. Germany Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 28. Germany Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 29. Germany Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 30. France Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 31. France Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 32. France Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 33. Italy Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 34. Italy Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 35. Italy Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 36. Spain Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 37. Spain Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 38. Spain Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 39. Norway Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 40. Norway Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 41. Norway Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 42. Denmark Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 43. Denmark Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 44. Denmark Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 45. Sweden Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 46. Sweden Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 47. Sweden Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 48. Asia Pacific Age-related macular degeneration market, country, 2021 - 2033 (USD Billion)
Table 49. Asia Pacific Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 50. Asia Pacific Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 51. Asia Pacific Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 52. Japan Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 53. Japan Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 54. Japan Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 55. China Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 56. China Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 57. China Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 58. India Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 59. India Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 60. India Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 61. Australia Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 62. Australia Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 63. Australia Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 64. South Korea Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 65. South Korea Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 66. South Korea Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 67. Thailand Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 68. Thailand Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 69. Thailand Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 70. Latin America Age-related macular degeneration market, country, 2021 - 2033 (USD Billion)
Table 71. Latin America Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 72. Latin America Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 73. Latin America Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 74. Brazil Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 75. Brazil Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 76. Brazil Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 77. Argentina Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 78. Argentina Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 79. Argentina Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 80. Middle East & Africa Age-related macular degeneration market, country, 2021 - 2033 (USD Billion)
Table 81. Middle East & Africa Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 82. Middle East & Africa Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 83. Middle East & Africa Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 84. South Africa Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 85. South Africa Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 86. South Africa Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 87. Saudi Arabia Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 88. Saudi Arabia Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 89. Saudi Arabia Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 90. UAE Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 91. UAE Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 92. UAE Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
Table 93. Kuwait Age-related macular degeneration market, product, 2021 - 2033 (USD Billion)
Table 94. Kuwait Age-related macular degeneration market, disease, 2021 - 2033 (USD Billion)
Table 95. Kuwait Age-related macular degeneration market, distribution channel, 2021 - 2033 (USD Billion)
List of Figures
Fig. 1 Age-related macular degeneration market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Competitive landscape
Figure 10 Age-related macular degeneration market dynamics
Figure 11 Age-related macular degeneration market: Porter’s five forces analysis
Figure 12 Age-related macular degeneration market: PESTLE analysis
Figure 13 Product market, 2021 - 2033 (USD Billion)
Figure 14 Eylea market, 2021 - 2033 (USD Billion)
Figure 15 Lucentis market, 2021 - 2033 (USD Billion)
Figure 16 Beovu market, 2021 - 2033 (USD Billion)
Figure 17 Others market, 2021 - 2033 (USD Billion)
Figure 18 Disease market, 2021 - 2033 (USD Billion)
Figure 19 Wet AMD market, 2021 - 2033 (USD Billion)
Figure 20 Dry AMD market, 2021 - 2033 (USD Billion)
Figure 21 Distribution channel market, 2021 - 2033 (USD Billion)
Figure 22 Hospital Pharmacy market, 2021 - 2033 (USD Billion)
Figure 23 Retail Pharmacy market, 2021 - 2033 (USD Billion)
Figure 24 Online pharmacy market, 2021 - 2033 (USD Billion)
Figure 25 Age-related macular degeneration market revenue, region
Figure 26 Regional marketplace: Key takeaways
Figure 27 North America Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 28 U.S. country dynamics
Figure 29 U.S. Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 30 Canada country dynamics
Figure 31 Canada Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 32 Mexico country dynamics
Figure 33 Mexico Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 34 Europe Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 35 UK country dynamics
Figure 36 UK Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 37 Germany country dynamics
Figure 38 Germany Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 39 France country dynamics
Figure 40 France Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 41 Italy country dynamics
Figure 42 Italy Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 43 Spain country dynamics
Figure 44 Spain Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 45 Norway country dynamics
Figure 46 Norway Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 47 Sweden country dynamics
Figure 48 Sweden Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 49 Denmark country dynamics
Figure 50 Denmark Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 51 Asia Pacific Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 52 Japan country dynamics
Figure 53 Japan Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 54 China country dynamics
Figure 55 China Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 56 India country dynamics
Figure 57 India Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 58 Australia country dynamics
Figure 59 Australia Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 60 South Korea country dynamics
Figure 61 South Korea Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 62 Thailand country dynamics
Figure 63 Thailand Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 64 Latin America Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 65 Brazil country dynamics
Figure 66 Brazil Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 67 Argentina country dynamics
Figure 68 Argentina Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 69 MEA Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 70 South Africa country dynamics
Figure 71 South Africa Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 72 Saudi Arabia country dynamics
Figure 73 Saudi Arabia Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 74 UAE country dynamics
Figure 75 UAE Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 76 Kuwait country dynamics
Figure 77 Kuwait Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 78 Company categorization
Figure 79 Company market position analysis
Figure 80 Strategic framework
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Competitive landscape
Figure 10 Age-related macular degeneration market dynamics
Figure 11 Age-related macular degeneration market: Porter’s five forces analysis
Figure 12 Age-related macular degeneration market: PESTLE analysis
Figure 13 Product market, 2021 - 2033 (USD Billion)
Figure 14 Eylea market, 2021 - 2033 (USD Billion)
Figure 15 Lucentis market, 2021 - 2033 (USD Billion)
Figure 16 Beovu market, 2021 - 2033 (USD Billion)
Figure 17 Others market, 2021 - 2033 (USD Billion)
Figure 18 Disease market, 2021 - 2033 (USD Billion)
Figure 19 Wet AMD market, 2021 - 2033 (USD Billion)
Figure 20 Dry AMD market, 2021 - 2033 (USD Billion)
Figure 21 Distribution channel market, 2021 - 2033 (USD Billion)
Figure 22 Hospital Pharmacy market, 2021 - 2033 (USD Billion)
Figure 23 Retail Pharmacy market, 2021 - 2033 (USD Billion)
Figure 24 Online pharmacy market, 2021 - 2033 (USD Billion)
Figure 25 Age-related macular degeneration market revenue, region
Figure 26 Regional marketplace: Key takeaways
Figure 27 North America Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 28 U.S. country dynamics
Figure 29 U.S. Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 30 Canada country dynamics
Figure 31 Canada Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 32 Mexico country dynamics
Figure 33 Mexico Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 34 Europe Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 35 UK country dynamics
Figure 36 UK Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 37 Germany country dynamics
Figure 38 Germany Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 39 France country dynamics
Figure 40 France Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 41 Italy country dynamics
Figure 42 Italy Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 43 Spain country dynamics
Figure 44 Spain Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 45 Norway country dynamics
Figure 46 Norway Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 47 Sweden country dynamics
Figure 48 Sweden Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 49 Denmark country dynamics
Figure 50 Denmark Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 51 Asia Pacific Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 52 Japan country dynamics
Figure 53 Japan Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 54 China country dynamics
Figure 55 China Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 56 India country dynamics
Figure 57 India Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 58 Australia country dynamics
Figure 59 Australia Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 60 South Korea country dynamics
Figure 61 South Korea Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 62 Thailand country dynamics
Figure 63 Thailand Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 64 Latin America Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 65 Brazil country dynamics
Figure 66 Brazil Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 67 Argentina country dynamics
Figure 68 Argentina Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 69 MEA Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 70 South Africa country dynamics
Figure 71 South Africa Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 72 Saudi Arabia country dynamics
Figure 73 Saudi Arabia Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 74 UAE country dynamics
Figure 75 UAE Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 76 Kuwait country dynamics
Figure 77 Kuwait Age-related macular degeneration market, 2021 - 2033 (USD Billion)
Figure 78 Company categorization
Figure 79 Company market position analysis
Figure 80 Strategic framework
Companies Mentioned
- Novartis AG
- Bayer AG
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals Inc.
- Amgen Inc.
- Biogen
- Samsung Bioepis
